Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EBP | Q15125 | 1/20 | 0.38 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.38 |
| ▸ | NPC1 | O15118 | 2/20 | 0.37 |
| ▸ | RAB9A | P51151 | 2/20 | 0.37 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.37 |
| ▸ | TP53 | P04637 | 1/20 | 0.37 |
| ▸ | HRH4 | Q9H3N8 | 1/20 | 0.37 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.37 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.36 |
| ▸ | NFKB2 | Q00653 | 1/20 | 0.36 |
| ▸ | RELA | Q04206 | 1/20 | 0.36 |
| ▸ | HPGD | P15428 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9866660 | 0.95 | NPY1R (0.37) | — | |
| SCHEMBL9865151 | 0.87 | EBP (0.41) | EBPSIGMAR1HRH4HRH3 | |
| SCHEMBL7180743 | 0.86 | HRH2 (0.37) | EBPSIGMAR1HRH4HRH3 | |
| SCHEMBL7287614 | 0.85 | HRH2 (0.47) | HRH4 | |
| SCHEMBL7287548 | 0.85 | HRH2 (0.47) | HRH4 | |
| SCHEMBL9867504 | 0.82 | HRH4 (0.40) | EBPSIGMAR1HRH4HRH3 | |
| SCHEMBL9877143 | 0.81 | HPGD (0.37) | EBPSIGMAR1NPC1RAB9AHRH4 | |
| Gapromidine SCHEMBL10372400 | 0.81 | CYP1A2 (0.40) | HRH4HRH3 | |
| SCHEMBL9865750 | 0.81 | RAB9A (0.43) | NPC1RAB9ASMN1; SMN2TP53HRH4 | |
| SCHEMBL9866282 | 0.81 | EBP (0.52) | EBPSIGMAR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-5021431-A | H-1 antagonist, h-2 agonist for treating hypertension, cardiac disease or arterial occlusion | HEUMANN PHARMA GMBH & CO. (DE) | 1991-06-04 | — | — | US | disclosed |
| EP-0199845-A1 | Imidazolylalkylguanidin derivatives, process for their preparation and pharmaceutical compositions containing them | HEUMANN PHARMA GMBH & CO (DE) | 1986-11-05 | — | — | EP | disclosed |